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Aim: This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune
globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%) in participants with primary humoral immunodeficiency (PI), compared with immune globulin injection (human), 10% caprylate/chromatography
purified (IGIV-C 10%). Patients & methods: About 53 participants enrolled. Total 44 received IGIVC 10% in the run-in phase and then entered the IV phase (with an additional nine who were already receiving IGIV-C 10% and entered the IV phase directly) for steady-state IV PK assessments. Total 49 entered the SC phase (weekly doses of IGSC-C 20% for ∼24 weeks). The PK profiles of IGIVC 10% and IGSC-C 20% and their safety and tolerability parameters were compared. Results: At a
dose adjustment factor of 1.37, IGSC-C 20% provided comparable (noninferior and bioequivalent) overall total immunoglobulin G exposure to IGIV-C 10% over an equal time interval. About 33 participants reported 79 adverse events during run-in + IV phases; 41 participants reported 141 adverse
events during the SC phase, with most being local infusion site reactions. The majority of infusion
site reactions were mild to moderate in severity. Conclusion: IGSC-C 20% was bioequivalent to IGIVC 10% and was well tolerated, with a safety profile comparable with IGIV-C 10%, in this study.
Trial registration: ClinicalTrials.gov identifier: NCT02604810
Lay abstract: This clinical trial studied a new US FDA-approved product, immune globulin subcutaneous,
human – klhw 20% solution (IGSC-C 20%), to treat primary humoral immunodeficiency (PI), a group of inherited disorders in which part of the immune system is missing or malfunctioning. Patients with PI may be
more susceptible to infections. This new product is a liquid medicine that is injected into the fat under the
skin and contains immunoglobulin G antibodies, which may be used to protect the body against infection.
Of the 53 enrolled participants, 42 (79%) completed the study. Results from this study showed that IGSC-C
20% acted similarly in the body as immune globulin injection (human), 10% caprylate/chromatography
purified (IGIV-C 10%), which is given in the vein and has been used for PI since 2003. IGSC-C 20% was well
tolerated and safe in adults and children, as young as 2 years old, in this study.
First draft submitted: 6 September 2019; Accepted for publication: 30 September 2019; Published
online: 17 October 2019
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As of February 2017, the International Union of Immunological Societies reported 344 different inborn errors
of immunity underlying 354 distinct disorders that compose primary immunodeficiency diseases, also known
globally by abbreviations PID or PIDD [1]. And with the rise of next-generation gene sequencing and increased
recognition of immune dysregulation diseases (i.e., autoinflammatory disorders and interferonopathies), this disease
landscape is evolving rapidly, with phenotypes as diverse as infection, malignancy, allergy, autoimmunity and
autoinflammation [1]. Primary humoral immunodeficiency (PI) consists of a heterogeneous group of genetic
disorders comprising the majority of primary immunodeficiencies. Patients with impaired humoral immunity are
highly susceptible to a wide range of infections, most commonly bacterial infections [2]. PI includes, but is not
limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia,
Wiskott–Aldrich syndrome and severe combined immunodeficiencies. Patients with PI are particularly susceptible
to serious bacterial infections of the respiratory tract as well as other infections [2,3]. In the USA one, approximately
one in 2000 children and one in 1200 persons (including adults and children) have primary immunodeficiencies,
and those needing antibody replacement receive regular infusions of immune globulin (Ig) as immune prophylaxis to
prevent recurrent infections [4,5]. Human Ig used for the treatment of PI consists of purified human immunoglobulin
G (IgG) obtained from multiple plasma donors and has been well established as an efficacious treatment of antibody
deficiency disorders [6,7]. Administration of Ig in a variety of IgG preparations can be carried out via intramuscular,
intravenous (IV) or subcutaneous (SC) route.
Over the past two decades, Ig given subcutaneously (IGSC) has become an increasingly popular route for IgG
replacement therapy [8]. Seven IGSC products, with IgG protein concentrations ranging from 10 to 20%, are
currently approved by the FDA to treat PI by SC administration [9–14]. However, only two of the seven FDAapproved IGSC products have 20% IgG protein concentration [10,11], and not all patients have access to these 20%
IgG formulations. The higher protein concentration of 20% products reduces infusion volume and allows shorter
infusion time, which makes them easier to administer subcutaneously. IGSC allows the flexibility of patient selfadministration and provides another treatment option for physicians and patients to treat PI without intravenous
infusions [12].
We report results on the pharmacokinetics (PK), safety and tolerability of this new IGSC-C 20% treatment
option in patients with PI from a recently completed, prospective, multicenter and Phase III clinical study
(NCT02604810). The investigational product in this study was the new Ig subcutaneous, human – klhw 20%
solution (IGSC-C 20%) approved by the FDA in July 2019 for the treatment of PI in patients 2 years of age
and older [13]. The second study drug, Ig injection (human), 10% caprylate/chromatography purified (IGIV-C
10%) [14], was employed in this trial to standardize IV Ig administration during the initial run-in phase and IV
phase.

Patients & methods
This study was sponsored by Grifols Therapeutics LLC (Research Triangle Park, NC, USA) and conducted by
Novella (NC, USA). The central laboratory was Covance (Indianapolis, IN, USA). Pharmacokinetic analyses were
done by Nuventra Pharma Sciences (NC, USA).

Study participants

All participants screened during the screening phase (lasting up to 28 days) had a confirmed diagnosis of primary
immunodeficiency, which included humoral and combined deficiencies (e.g., hyper IgM syndrome and severe combined immunodeficiency post-transplantation), as defined by the Pan-American Group for Immunodeficiency and
the European Society for Immunodeficiencies [2], and were clinically stable on replacement immunoglobulin with
a screening IgG trough ≥500 mg/dl. A complete list of inclusion and exclusion criteria is in Supplementary Table
1. About 50 participants were planned for enrollment to provide 30 completing adults and 12–18 completing
children, with a target of four to six children for each age group (≥2–5, >5–12 and >12–16 years). The planned
minimum enrollment of 42 completing participants provided ≥90% power to demonstrate that the area under
the curve (AUC) for total IgG for IGSC-C 20% was noninferior to that achieved by IGIV-C 10%, assuming the
intrasubject coefficient of variation was no greater than 30%.
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Study product
R
The study drug IGSC-C 20% (XEMBIFY
[Ig subcutaneous, human – klhw] 20% solution) [13] is a new product
manufactured with the same caprylate/chromatography purification process and stabilizer (glycine) as IGIV-C
R
-C [Ig injection (human), 10% caprylate/chromatography purified] [14]. Both IGSC-C 20% and
10% (Gamunex
IGIV-C 10% are manufactured by Grifols Therapeutics LLC (Research Triangle Park, NC, USA) from large pools
of human plasma by a combination of cold ethanol fractionation, caprylate precipitation and filtration, and anionexchange chromatography. IGSC-C 20% is a ready-to-use sterile, nonpyrogenic solution of high purity (≥98%)
human IgG protein for subcutaneous infusion, with a final formulation of 20% (w/v) protein concentration, a pH
of 4.1–4.8, trace amounts of IgA and IgM, and an osmolality of about 340 mOsmol/kg.

Study design

This prospective, multicenter, open-label, single-sequence and Phase III study (Figure 1) took place between 4
January 2016 and 14 December 2017. The primary PK objective of this study was to determine a weekly dose of
IGSC-C 20% that produced steady-state AUC of total IgG that was noninferior to that of the regularly administered
dose of IGIV-C 10% in participants with PI. The secondary PK objective was to determine whether IGSC-C 20%
replacement therapy maintained mean steady-state trough of total IgG levels that were comparable with IGIV-C
10%. The safety objective was to assess the safety and tolerability of IGSC-C 20% as an IgG replacement therapy
in participants with PI. This study also evaluated several exploratory objectives, including trough levels of IgG
subclasses, maximum concentration (Cmax ) and time to reach maximum concentration (tmax ) at steady state, rate
of serious bacterial infections, all infections of any kind as determined by the investigator, validated infections;
number of days on antibiotics, use of prophylactic antibiotics, number of hospitalizations due to infection, and
number of days of work/school/daily activities missed due to infections and their treatment.
The study consisted of a screening phase, a run-in phase, an IV phase, a SC phase and an end of study/early
termination visit (Figure 1). The run-in phase was included to allow participants, who were not receiving IGIV-C
10% at 300–800 mg/kg per infusion every 3–4 weeks for ≥3 consecutive months before screening, to reach an
approximate steady-state condition prior to PK profiling in the IV phase. The IV phase served as the reference
(control) study phase in that the primary objective of noninferiority for IgG exposure under approximate steadystate conditions would be determined by comparing the AUC for SC dosing (AUCsc ) of IGSC-C 20% against
that from IV dosing (AUCIV ) of IGIV-C 10%. Participants who went through the IV phase received the same
dose of IGIV-C 10% as had been administered when they were in the run-in period. During the SC phase,
participants received weekly SC doses of IGSC-C 20% for 24 weeks. The dosing regimen for IGSC-C 20% was
based on literature data of the bioavailability of SC administered IgG and prior experience with IGIV-C 10% given
subcutaneously [15–19]. The weekly IGSC-C 20% dosing regimen (1.37-times the IV dose of IGIV-C 10% divided
by either 3 or 4 weeks depending on the dosing interval) was predicted to provide a noninferior steady-state IgG
AUC to that of the prior IGIV-C 10% dose based on established bioequivalence criteria. The PK profiles were
assessed for all participants. Participants aged 2–5 years old had an abbreviated sampling schedule for PK profiles.
Participants and investigators were allowed to tailor the number of injection sites, infusion rate and the specific
times of the day for the SC infusion. Up to eight infusion sites (≥5 cm apart) per infusion were allowed, and
participants were allowed to use the same anatomical area or rotated anatomical areas for SC infusions throughout
the study. The target infusion rate was ≤25 ml/h/site, depending on tolerability. Once the target infusion rate
was achieved, it was not changed in the middle of an infusion unless the subject experienced tolerability issues at
that infusion rate. In the event, the subject was not able to tolerate a set infusion rate, the rate could be decreased
for better tolerability. Conversely, if the target infusion rate was well tolerated during two infusions, an increase of
20% in infusion rate and volume per site was allowed at the discretion of the investigator.
An interim PK analysis was conducted on eight participants (aged 27–72 years) to confirm that a SC dose
adjustment factor (DAF) of 1.37 was adequate. The DAF was deemed acceptable if the ratio of geometric least
squares mean (GLSM) for the area under the concentration-time curve from 0 to 7 days following SC infusion
(AUC0–7,SC ) versus the adjusted area under the concentration-time curve from 0 to 7 days following IV infusion
(AUC0-7,IV ) was ≥0.9. Data from this interim analysis yielded a ratio of 0.95, mean trough IgG values ≥757 mg/dl
for individual participants receiving IGSC-C 20%, and an average mean trough IgG level across participants of
1169 mg/dl. Thus, the DAF of 1.37 was acceptable, and no modification was warranted.
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IV phase

Subjects on
qualifying IGIV-C
regimen proceed
directly to IV phase

IGIV-C 10%
dose:
300–800 mg/kg
Dosing interval:
3 or 4 weeks

IV#1

Screening

IV#2

SC phase
IGSC 20% dose: (300–800 mg/kg ÷ [3 or 4]) × 1.37
Dosing interval: weekly

SC#1

Run-in phase

SC#2

SC#3

SC#5

SC#9

SC#13

SC#14

SC#17

SC#21

Monthly extension
visits
(pending interim
analysis)

Blood sampling
visits
2–4 days post
SC#1 & SC#2

IGIV-C 10% dose:
300–800 mg/kg
Dosing interval:
3 or 4 weeks
PK for IV AUC
pre-dose & postdose: 0, 1 h, 3–16 h,
and 1, 2, 3, 5, 7, 14,
21, 28a days

Wk#25b

PK for SC AUC
pre-dose & postdose: 1, 3, 4, 5, 7,
days

The underlined time points for IV and SC AUC PK profiles represent abbreviated sampling schedules for 2–5 year old subjects

Up to 28
days

b

3–4 months

4–5 weeks

24 weeks

a
Only applicable to subjects who are on a 4-week dosing interval
Week #25 = final visit (week #25)/early termination visit

Figure 1. Study design. Study entry point was determined at screening based on the most recent IgG treatment history of each subject.
During the screening phase of up to 28 days following the first assessment of subject eligibility, participants were categorized into three
groups. Group 1: Participants who were receiving a stable (≥3 months) dose of IV IGIV-C 10% between 300 and 800 mg/kg per infusion
every 3 or 4 weeks did not need to enter the run-in phase and proceeded directly to the IV phase; these participants had their IV#1 visit
scheduled to coincide with the date for their next IV infusion according to their regular dosing interval (τ) and came to the clinic for this
visit. Group 2: Participants who had been receiving a different commercially available IGIV therapy other than IGIV-C 10% at a dose
between 300 and 800 mg/kg per infusion every 3 or 4 weeks were required to receive IGIV-C 10% intravenously (at an equivalent dose
and dosing interval as in their previous IGIV therapy) for a total duration of a 3-month run-in phase; participants receiving infusions every
3 weeks had four run-in visits and participants receiving infusions every 4 weeks had three run-in visits. Group 3: Participants were
required to participate in a 4-month run-in phase if they had been receiving SCIG prior to screening, or if they had been receiving IGIV
therapy other than IGIV-C 10% but had not been on a stable dose for the 3 months prior to screening OR the dose was not between 300
and 800 mg/kg OR who received IGIV infusions that were not administered at a frequency of every 3 or 4 weeks. Participants meeting any
of the criteria for Group 3 were scheduled to begin receiving IGIV C 10% intravenously at a dose of 300–800 mg/kg every 3 to 4 weeks
(dose and interval were determined based on the investigator’s clinical judgment) for a period of up to 4 months prior to the IV#1 visit.
Participants receiving infusions every 3 weeks had five run-in visits and participants receiving infusions every 4 weeks had four run-in
visits. The AUC from the IV phase of the study was calculated based on trough-to-trough measurements around the IV#1 infusion. Blood
samples were taken immediately prior to the infusion and then at specified times (for 3–4 weeks depending on dosing interval); the last
blood-draw for AUC for IV dosing (AUCIV ) occurring just before the IV#2 infusion. The SC phase occurred 1 week after the second IV dose
(IV#2). The IGSC-C 20% dose was determined using an initial IV to SC dose adjustment factor of 1.37. To determine a SC DAF, a
comparison of the IV PK profiles and SC PK profiles in the first eight participants (age ≥12 to 75 years) was performed through an interim
PK analysis. Since a DAF of 1.37 was deemed acceptable (SC dose of IGSC-C 20% was noninferior to the subject’s IV dose), all participants
continued and completed treatment and assessments through Week #25 (no further monthly extension visits). PK profiles were assessed
in all participants. Participants aged 2–5 years old were assessed using an abbreviated sampling schedule (underlined time points) for PK
profiles. The first three weekly SC doses were administered in the clinic to ensure the subject utilized the proper self-administer
techniques. SC infusions 5, 9, 17 and 21 were performed in the clinic to obtain total IgG trough levels before beginning the infusion. The
remaining weekly SC infusions were self-administered at home. After 12 weeks of weekly SC therapy, determination of PK profiles for
total IgG during the SC phase began just prior to the 13th SC infusion with the last sample collected immediately prior to the 14th SC
infusion (7 days total).
AUC: Area under the concentration versus time curve; DAF: Dose adjustment factor; IGIV-C 10%: Immune globulin injection (human), 10%
caprylate/chromatography purified (Grifols); IGSC-C 20%: Immune globulin subcutaneouss (human), 20% caprylate/chromatography
purified (Grifols); IGIVl: Intravenous immune globulin (generic terminology); IV, intravenous; PK: Pharmacokinetic/pharmacokinetics; SC:
Subcutaneous; SCIG: Subcutaneously delivered immune globulin or subcutaneous immunoglobulin (generic terminology).
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All participants received study drug treatment in the same order (i.e., IV infusion of IGIV-C 10% followed
by SC infusion of IGSC-C 20%). The duration of the IGSC-C 20% phase was approximately 24 weeks for all
participants.
Statistical analyses

Descriptive statistics were calculated as appropriate for the type of end points (continuous/quantitative or
categorical/qualitative). Geometric mean and 90% CI were calculated for PK parameters (except tmax ). The safety
population included participants who received any amount of study drugs (IGIV-C 10% and/or IGSC-C 20%).
The IgG population consisted of participants who received study drugs and had any total IgG concentration data.
The PK population consisted of all participants who received study drugs and had sufficient, valid data to calculate
steady-state AUC0-τ,SC or AUC0-τ,IV , which were analyzed by analysis of variance with a mixed-effect model. PK
parameters were calculated using standard noncompartmental methods. For infection-related end points, the rate
per person per year and associated 95% CI were calculated using a generalized linear model for Poisson regression.
Results
Participants

Of the 61 participants screened by 20 study centers from the USA and Canada, 53 entered the study (safety
population and IgG population), and 50 were evaluable for the PK analysis population (Supplementary Figure
1). Three participants were excluded from the PK population due to withdrawal from the run-in phase (n = 1)
and the lack of sufficient total IgG data for AUC calculations (n = 2). About 49 participants completed the IV
phase and entered the SC phase, receiving weekly IGSC-C 20% for approximately 24 weeks, with PK profiling
at SC week #13–14. Of the 53 who entered the study, 42 participants (79.2%) completed the study, and 11
participants (20.8%) discontinued the study prematurely due to adverse events (AEs) (n = 5), withdrawal by subject
(n = 4), lost to follow-up (n = 1) and other reason (n = 1). Pediatric enrollment occurred as per protocol; only two
participants were enrolled in the ≥2 to ≤5 year age group despite significant efforts to identify participants for this
age category. Table 1 shows the demographics and baseline characteristics for the safety population. The average
(standard deviation [SD]) time from diagnosis of PI to study entry was 10.3 (10.7) years (Table 2); there were no
major differences in the history of PI and IgG treatment across age groups. The most frequently associated medical
diagnoses were asthma (37.7%; 20 of 53) and allergic rhinitis (35.8%; 19 of 53).
Pharmacokinetic parameters

Primary PK end points were analyzed for three versions of the PK population: the full PK population (n = 49 in IV
phase and n = 39 in SC phase), the PK population with the original eight participants used in the interim analysis
excluded, and only participants in the PK population with sufficient and valid serial PK profiles that allowed the
calculation of the AUC parameter in both the IV and SC phases. At a DAF of 1.37, the GLSM ratio (SC/IV) for
the primary PK end point of steady state AUC0–7 days ranged from 1.04 (90% CI: 1.00–1.07) to 1.06 (90% CI:
1.03–1.10), demonstrating that SC administration of IGSC-C 20% is noninferior and bioequivalent to regularly
administered IV dose of IGIV-C 10% (Figure 2A), and there was no difference between age groups (data not
shown).
Results from the IV phase (n = 49), including participants who received IV doses of IGIV-C 10% every 3 weeks
(n = 6) and every 4 weeks (n = 43), showed the average (SD) predose IgG trough (i.e., prior to infusion IV#1) was
964 (242) mg/dl. At the completion of the first IV infusion, the average total IgG concentration rose to 2075 (396)
mg/dl, followed by a decrease to 913 (192) mg/dl at the end of the 4-week dosing interval. The average predose
IgG trough prior to SC#13 infusion of IGSC-C 20% was 1253 (279) mg/dl, and all participants maintained IgG
levels >580 mg/dl during the SC phase. Unlike the IV phase, which exhibited a clear peak in IgG concentration
followed by an elimination phase, average total IgG concentrations following SC administration remained relatively
stable, with only small fluctuations from preinfusion through 7 days post-SC infusion. The peak IgG level occurred
at an average of 76 h after IGSC-C 20% infusion. Average total IgG concentrations over 7 days of the PK profiling
during the SC#13 dosing interval ranged from the lowest of 1263 (294) mg/dl to the highest of 1358 (279) mg/dl.
Infection rates

The number of participants with SBIs, validated infections and infections of any kind were similar between the IV
and SC phases. Table 3 shows infection results for the combined run-in + IV and SC phases. No SBI was reported
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Table 1. Demographics and baseline characteristics (safety population).
Demographic variables

Total (n = 53)

Age, years
Age category, years

Sex

Ethnicity

Race

Mean ± SD or n (%)

Median (min–max)

36.8 ± 21.36

39.0 (2–72)

≥2 to ≤5

2 (3.8)

-

⬎5 to ≤12

7 (13.2)

-

⬎12 to ≤16

6 (11.3)

-

⬎16

38 (71.7)

-

⬎16 to ≤65

34 (64.2)

-

⬎65

4 (7.5)

-

Male

27 (50.9)

-

Female

26 (49.1)

-

Hispanic or Latino

5 (9.4)

-

Non-Hispanic or -Latino

48 (90.6)

-

White

48 (90.6)

-

Black or African–American

2 (3.8)

-

American–Indian or Alaska Native

3 (5.7)

-

Height, cm

160.0 ± 20.9

164.0 (88.0–187.0)

Weight, kg

68.4 ± 25.5

66.5 (16.7–123.8)

934.7 ± 230.8

917.5 (545–1740)

Subject entered in 3-month run-in
phase

19 (35.8)

-

Subject entered in 4-month run-in
phase

25 (47.2)

-

Baseline total IgG,† mg/dl (n = 52)
Subject entry status

Subject entered directly into IV phase

9 (17.0)

-

Frequency of subject IV dose at entry
(run-in or IV phase)

Every 3 weeks

6 (11.3)

-

Every 4 weeks

47 (88.7)

-

Assigned IV dose at entry,‡ mg/kg

Every 3 weeks

393.0 ± 64.8

387.5 (324.0– 483.0)

Every 4 weeks

519.2 ± 139.6

506.0 (300.0– 800.0)

† Baseline

total IgG concentration is the last measurement taken prior to the start of the study drug infusion at run-in visit 1 for participants who were enrolled into the run-in phase, or
at the IV#1 visit for participants who were enrolled directly into the IV phase.
IV dose at entry is taken from run-in visit 1 for participants who were enrolled into the run-in phase, or at the IV#1 visit for participants who were enrolled directly into the IV
phase.
IgG: Immunoglobulin G; IV: Intravenous; SD: Standard deviation.
‡ Assigned

during the run-in phase. During the IV phase, two SBIs (pneumonia and sepsis) occurred in one participant (1.9%,
1/52). During the SC phase, one SBI (due to an animal bite leading to sepsis and cellulitis) was reported in one
participant (2.0%, 1/49). All SBIs were treated and resolved. The rate of SBIs was 0.049 (95% CI: 0.020–0.098;
upper 99% confidence limit: 0.110) events per subject-year during IGSC-C 20% treatment and 0.120 (95% CI:
0.051–0.232; upper 99% confidence limit: 0.259) in the combined run-in + IV phase. These annual rates were
lower than 1.0 SBI/year, the threshold specified as providing substantial evidence of efficacy while receiving IgG
replacement therapy [17,18].
The incidences of validated infections were similar between the combined run-in + IV phases and SC phase.
In the combined run-in + IV phases, 15.1% (eight of 53) of participants had ≥1 validated infection, and in the
SC phase, 16.3% (eight of 49) of participants had ≥1 validated infection. The rate of validated infections per
person per year was comparable between the IV phases and SC phase: combined run-in + IV of 0.658 (95%
CI: 0.378–1.051) and SC phase of 0.493 (95% CI: 0.273–0.809). The validated infections that occurred in ≥2
participants in the combined run-in + IV phases were urinary tract infection and in the SC phase were cellulitis,
pharyngitis streptococcal and urinary tract infection. Infections of any kind occurred in 50.9% (27/53) and 53.1%
(26/49) of participants during the run-in + IV and the SC phases, respectively.
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Table 2. Summary of primary immunodeficiency and immunoglobulin G treatment history (safety population).
Total (n = 53)
Time since primary immunodeficiency diagnosis, years
– Mean ± SD

10.3 ± 10.7

– Median

6.7

– Min–max

0.3–41.1

Type of primary immunodeficiency, n (%)
– Common variable immunodeficiency

41 (77.4)

– X-linked agammaglobulinemia

5 (9.4)

– Hyper IgM immunodeficiency syndrome

2 (3.8)

– Primary hypogammaglobulinemia

2 (3.8)§

– Severe combined immunodeficiency (post-transplantation)

2 (3.8)

– Autosomal recessive agammaglobulinemia

1 (1.9)

Frequency of IgG treatment† by route of administration for past 12 months, n (%)
• IV administration:
– Every 3 weeks

6 (11.3)

– Every 4 weeks

29 (54.7)

• SC administration:
– Every week

15 (28.3)

– Every 2 weeks

5 (9.4)

– Every 4

weeks‡

6 (11.3)

† IgG

treatments are not mutually exclusive.
‡ All SC and every-4-week IgG treatments were HYQVIA (immune globulin infusion 10% [Human] with recombinant human hyaluronidase) solution for subcutaneous administration
(Baxalta, MA, USA) [16].
§ Both patients with primary hypogammaglobulinemia were children and were diagnosed with PI for over 2.5 years prior to study participation, and were maintained on SC immunoglobulin
replacement prior to the study in order to provide adequate total IgG trough levels.
IgG: Immunoglobulin G: IV: Intravenous; SC: Subcutaneous; SD: Standard deviation.

Table 3. Summary of infections and associated events.
Parameters

Run-in + IV phase, rate (95% CI)
(n = 53)

SC phase, rate (95% CI)
(n = 49)

Total number of subject-years on treatment

16.73

20.28

Annual rate of any infections† (per subject-year)

2.750
(1.937–3.764)

2.367
(1.601–3.345)

Annual rate of validated infections‡ (per subject-year)

0.658
(0.378–1.051)

0.493
(0.273–0.809)

Days on antibiotics (prophylactic)§ (rate per subject-year)

34.080
(17.842–58.045)

27.660
(13.647–49.011)

Days on antibiotics (therapeutic) (rate per subject-year)

18.535
(12.102–26.922)

28.893
(17.291–44.792)

Days missed work/school/unable to perform normal daily activities due to
infections (rate per subject-year)

3.049
(1.584–5.221)

2.268
(1.055–4.174)

Serious bacterial infection (rate per subject-year)

0.120¶
(0.051–0.232)

0.049
(0.020–0.098)

Number of hospitalizations due to infections (rate per subject-year)

0.060
(0.025–0.116)

0.049
(0.020–0.098)

† Infection refers to infection of any kind (serious/nonserious including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, pneumonia, acute bronchitis,
infectious diarrhea, etc.) as determined by the investigator.
‡ Validated infections as documented by positive radiograph, fever (⬎38◦ C oral or ⬎39◦ C rectal), culture or diagnostic testing for microorganisms, for example, bacterial, viral,
fungal or protozoal pathogens (for instance, rapid streptococcal antigen detection test).
§ Use of prophylactic antibiotics was distinguished from antibiotics used for the treatment of acute infection.
¶ No SBI was reported during the run-in phase. In the IV phase, one participant had pneumonia and sepsis, and in the SC phase one participant had cellulitis and sepsis due
to an animal bite; these events are also accounted for in Table 6 as serious adverse events.
Antibiotics included oral, parenteral, oral plus parenteral, prophylactic and therapeutic antibiotic treatments.
IV: Intravenous; SBI: Serious bacterial infection; SC: Subcutaneous.
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Figure 2. Mean total Immunoglobulin G concentrations (mg/dl). (A) Serial total IgG concentrations following IGIV-C
10% administration at IV#1 and IGSC-C 20% administration at SC#13. Inset table shows the statistical analysis results
on the primary PK end point of steady state AUC 0–7 days of total IgG using the PK population. GLSMs, GLSM ratio and
90% CI of GLSM ratio are determined from a mixed-effect model with the log-transformed AUC 0–7 days as the
response variable, study phase as a fixed effect and subject as a random effect. AUC0–21 days or AUC0–28 days in the IV
phase was standardized to AUC0–7 days by dividing it by 3 or 4, depending on the IV dosing schedule. (B) Trough
(predose) total IgG concentrations. Inset table shows the summary statistics using the IgG population. Mean trough in
the IV phase is calculated as the average of the trough concentrations at the IV#1 and IV#2 visits. Mean trough in the
SC phase is calculated as the average of the trough concentrations at the SC#13, SC#14, SC#17 and SC#21 visits.
AUC: Area under the curve; CV: Coefficients of variation; IGIV-C 10%: Immune globulin injection (human), 10%
caprylate/chromatography purified (Grifols); IGSC-C 20%: Immune globulin subcutaneous (human), 20%
caprylate/chromatography purified (Grifols); GLSM: Geometric LSM; IV: Intravenous; LSM: Least-squares mean; PK:
Pharmacokinetic; SC: Subcutaneous.

Trough total IgG, IgG subclasses & antibody titers

Trough concentrations of total IgG are summarized in Figure 2B, along with the mean trough total IgG concentration during the IV and SC phases. The average (SD) of the steady-state mean trough concentrations of total IgG
over all participants during the IV phase was approximately 957 (242) mg/dl. All individual trough concentrations,
except for one subject, were above the commonly accepted protective trough concentration of 500 mg/dl [19].
There was a relatively small range of variation, with mean trough coefficients of variation (CV%) of 25.3%, which
included a trend toward slightly higher trough values for the six participants with a 3-week dosing interval. The
trough IgG concentration in the SC phase was consistent across the four visits, with CV% ranging from 23 to 24%.
The average (SD) of the mean SC trough IgG concentrations over all participants was approximately 1245 (272)
mg/dl and was generally higher than the average of the mean IV trough IgG concentrations, with an average mean
trough ratio (SC:IV) of 1.333. All individual trough concentrations in the SC phase were also above the accepted
500 mg/dl therapeutic threshold [20].
The results for IgG subclasses (IgG1, IgG2, IgG 3 and IgG4) in the two study phases were consistent with total
IgG trough levels by visit (Supplementary Table 2). Trough IgG subclasses reached a steady state by at least SC week
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Table 4. Trough concentrations of pathogen antibody titers during the IV and subcutaneous phases (immunoglobulin G
population).
Pathogen type

Statistic

IV phase

SC phase

Final visit/early
termination visit

IV#1 visit

IV#2 visit

SC#9 visit

SC#17 visit

Hemophilus
influenzae (μ g/ml)

n
Mean ± SD
Min–max

49
5.4 ± 9.5
0.4–64.0

49
5.0 ± 8.8
0.5–60.8

43
6.6 ± 9.1
0–60.9

41
6.4 ± 9.7
1.1–63.9

49
8.5 ± 14.5
0.9–89.3

Clostridium tetani
(IU/ml)

n
Mean ± SD
Min–max

49
4.5 ± 2.2
1.2–10.5

49
4.5 ± 2.6
0.9–16.1

43
6.5 ± 2.9
2.1–14.7

41
6.4 ± 2.7
2.4–13.0

49
7.1 ± 3.4
0.8–17.4

Measles† (IU/ml)

n
Mean ± SD
Min–max

—
—
—

51
1.5 ± 1.2
0.3–8.0

—
—
—

—
—
—

47
1.6 ± 0.9
0.4–6.3

† Trough samples for measles antibody titer were collected at IV#2 (before the first SC infusion of IGSC-C 20%) and at SC week #52, and then measured by functional assay.
IgG: Immunoglobulin G; IV: Intravenous; SC: Subcutaneous; SD: Standard deviation.

#9, remained proportionally similar in both study phases, and were also generally consistent across the different
age groups (data not shown).
The trough levels of antibodies for Hemophilus influenzae, Clostridium tetani and measles are shown in Table 4.
Data for Streptococcus pneumoniae subtypes are shown in Supplementary Table 3. For H. influenzae, C. tetani and
S. pneumoniae, serum trough concentrations were generally consistent across all age groups (data not shown). After
switching from IV to SC administration, the average trough levels of these antibodies increased, and the increases
remained through the final study visit. The trough concentrations of measles antibody were comparable between
the IV and SC phases (Table 4), except for the ≥2 to ≤5 year age group (n = 2) which had increased from a
mean of 0.475 IU/ml in the IV phase to 1.120 IU/ml in the SC phase. All measles antibody titers were protective
(i.e., minimum range in excess of 0.24 IU/ml) [21,22].
Subcutaneous administration characteristics

Table 5 summarizes the administration characteristics of IGSC-C 20% in this study. Most SC infusions were
conducted using either four infusion sites (56.2%, 592 of 1053 infusions) or two infusion sites (30.5%, 321 of
1053 infusions). When analyzed by age groups, it appears that younger participants (≥2 and ≤5 years of age,
n = 2) preferred to use two sites (86.2%, 25 of 29 infusions). There was a gradual increase in use of four infusion
sites as age increased. Older participants (>16 years old) typically used four sites (69.6%, 525 of 754 infusions).
Infusion volume was influenced by the age of the participants. The younger the participants were, the less volume
was required to provide the specified mg/kg dose of IGSC-C 20%. The mean (SD) duration per infusion for the
SC phase was 1.6 (0.8) h, which is relatively shorter than 2.19 (1.02) h for the run-in phase and 2.30 (1.04) h for
the IV phase. IGSC-C 20% was given with the mean (SD) dose of 179 (45) mg/kg/week for a median treatment
duration of 24 weeks (mean [SD], 21.6 [6.5] weeks). The median (range) dose was 171 (71–276) mg/kg/week.
The total exposure of IGSC-C 20% was 20.28 subject-years and 1053 infusions (Tables 3 & Supplementary
Table 4).
Safety & tolerability

About 53 participants received a total of 261 IGIV-C 10% infusions during the combined run-in + IV phases, and
49 participants received a total of 1053 IGSC-C 20% infusions during the SC phase (Table 6). The majority of AEs
in this study were deemed mild (63.3%, 50/79, run-in + IV; 60.3%, 85/141, SC) or moderate (35.4%, 28/79,
run-in + IV; 36.2%, 51/141, SC) in severity. Before any treatment initiation, 22.6% (12 of 53) of participants
experienced ≥1 AE, mostly related to pre-existing medical conditions. During the run-in + IV phases, a total of
79 AEs occurred in 62.3% (33 of 53, 0.303 event per infusion) of participants, and 141 AEs occurred in 83.7%
(41 of 49, 0.134 event per infusion) of the participants during the SC phase – most of which were local infusion
site AEs associated with the SC route of administration (Table 7).
The incidences of potentially related AEs were similar between the run-in + IV (0.050 event per infusion) and
SC phases (0.058 event per infusion). During the run-in + IV phases, 15.1% (eight of 53) of participants had
13 potentially infusion-related AEs, including two headaches (3.8%, two of 53; 0.008 event per infusion) and
one each (1.9%, one of 53; 0.004 event per infusion) of abdominal discomfort, asthma, positive Coombs direct

future science group

www.futuremedicine.com

1379

Research Article

Sleasman, Lumry, Hussain et al.

Table 5. Summary of subcutaneous administration characteristics (safety population).
SC Infusions

SC phase (n = 49)

Total number of SC infusions

1053

Number of infusion sites used per infusion, mean ± SD
Number of infusion sites used per

infusion,†

3.3 ± 1.1

n (% of infusions)

–1

30 (2.8)

–2

321 (30.5)

–3

86 (8.2)

–4

592 (56.2)

–6

24 (2.3)

Distribution of SC infusion sites
Total number of participants infused‡

49

– Abdomen, n (%)

46 (93.9)

– Thigh, n (%)

19 (38.8)

– Buttocks, n (%)

3 (6.1)

– Side(s), n (%)

3 (6.1)

– Arm, n (%)

1 (2.0)

– Back, n (%)

1 (2.0)

– Hip, n (%)

1 (2.0)

Total number of SC infusion sites used§

3442

– Abdomen, n (%)

2513 (73.0)

– Thigh, n (%)

746 (21.7)

– Buttocks, n (%)

83 (2.4)

– Arm, n (%)

46 (1.3)

– Side(s), n (%)

32 (0.9)

– Back, n (%)

18 (0.5)

– Hip, n (%)

4 (0.1)

Dose (mg/kg/week), mean ± SD

179 ± 45

Duration of treatment period (week), mean ± SD

21.6 ± 6.5

Volume infused per site per infusion (ml/site),¶ mean ± SD

20.6 ± 11.5

Infusion rate per site per infusion (ml/hour/site),# mean ± SD

16.0 ± 6.9

Duration of infusion (h), mean ± SD

1.6 ± 0.8

By-subject maximum volume infused per site per infusion (ml/site), mean ± SD

23.5 ± 20.3

By-subject maximum infusion rate per site per infusion (ml/h/site), mean ± SD

17.5 ± 8.1

† The

denominator for the percentages is the total number of SC infusions.
infusion sites are not mutually exclusive. The denominator for the percentages is the total number of participants infused.
§ The denominator for the percentages is the total number of SC infusion sites used.
¶ Volume infused per site (ml/site) = total volume infused (ml)/total number of infusion sites.
#
Infusion rate per site (ml/h/site) = total infusion rate (ml/h)/total number of infusion sites.
SC: Subcutaneous; SD: Standard deviation.
‡ SC

test, positive Coombs test, cough, granulocytopenia, laryngitis, procedural vomiting, proteinuria, rash pustular and
sinusitis. Systemic AEs were low during the SC phase with only one report of headache related to infusions (2.0%,
one of 49; 0.001 event per infusion). All but one of the potentially related AEs in the SC phase were also mild or
moderate severity. The one subject, who experienced a severe potentially related AE during the SC phase (on day
20), had polymyalgia rheumatica which was considered unlikely related to study drug and resolved by day 75.
There were more participants with AEs during or within 72 h of an infusion in the SC phase (71.4%, 35 of 49,
0.087 event per infusion) than in the run-in + IV phases (18.9%, ten of 53, 0.042 event per infusion). Most were
local infusion site AEs associated with the SC route of administration, and the percentage of participants reporting
local ISRs declined over time. At the beginning of the SC phase (visit SC#1), 34.7% (17 of 49) of participants
reported local ISRs. Then at visit SC#12, 18.2% (eight of 44) reported local ISRs, and by the end of the SC phase
after 24 infusions, only 14.3% (6 of 42) reported local ISRs. These time-related changes reflect a >50% decrease
in local ISRs from the beginning of the SC phase as participants continued to receive weekly SC infusions.
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Table 6. Overall summary of adverse events during study phases (safety population).
Run-in + IV phases

Parameters

Patients, n (%)†
(n = 53)

SC phase

Events per infusion, n
(rate)‡
(n = 261)

Patients, n (%)†
(n = 49)

Events per infusion, n
(rate)‡
(n = 1053)

Overall summary of adverse events
Any AE

33 (62.3)

79 (0.303)

41 (83.7)

141 (0.134)

Any potentially related AE

8 (15.1)

13 (0.050)

21 (42.9)

61 (0.058)

Any AE during or within 72 h of an infusion

10 (18.9)

11 (0.042)

35 (71.4)

92 (0.087)

Any definitely related AE

0

0

14 (28.6)

42 (0.040)

Any serious adverse event

1 (1.9)§

2 (0.008)

2 (4.1)¶

4 (0.004)

AE leading to discontinuation

1 (1.9)#

2 (0.008)

4 (8.2)††

9 (0.009)

Any potentially related SAE

0

0

0

0

Death

0

0

0

0

† Number

and percentage of participants with the event.
per infusion is calculated as the total number of events divided by the total number of infusions.
was no SAE reported during the run-in phase. During the IV phase, one participant had SAEs (pneumonia bacterial and sepsis) that were considered moderate in severity
and deemed unrelated to the study drug by the investigator. These SAEs resolved, and the participant recovered but subsequently withdrew from the study.
¶ During the SC phase, two participants had SAEs that were considered severe in severity and deemed unrelated to the study drug by the investigator. One of the two participants
had cellulitis and sepsis due to an animal bite after receiving the first SC infusion; this case was also accounted for in Table 3 as serious bacterial infection. These SAEs resolved.
Another participant, who had a history of cervical problems, experienced intervertebral disc degeneration after the first SC infusion. Both participants completed the study.
#
One participant discontinued IGIV-C 10% due to AEs (pneumonia, sepsis) which were considered moderate in severity, serious, not study drug related, and were all treated
and resolved.
†† Four participants discontinued IGSC-C 20% due to AEs. Three participants had three nonserious local ISRs (infusion site nodules, infusion site discomfort and skin
papules/plaques) that were considered mild or moderate in severity and definitely related to study drug. One subject reported arthralgia and myalgia that was considered
nonserious, moderate in severity, and possibly related to study drug. All but two of the AEs resolved.
AE: Adverse event; IGIV-C 10%: Immune globulin injection (human), 10% caprylate/chromatography purified (Grifols); IGSC-C 20%: Immune globulin subcutaneous (human),
20% caprylate/chromatography purified (Grifols); IV: Intravenous; SAE: Serious adverse event; SC: Subcutaneous.
‡ Rate

§ There

Table 7. Systemic Adverse events and all local infusion site reactions in ≥5% participants during immune globulin
subcutaneous (human), 20% caprylate/chromatography purified (Grifols) infusions† .
Patients, n (%)‡ (n = 49)

Events per infusion, n (rate)§ (n = 1053)

– Cough

3 (6.1)

4 (0.004)

– Diarrhea

3 (6.1)

3 (0.003)

– Infusion site erythema

19 (38.8)

123 (0.117)

– Infusion site pain

9 (18.4)

32 (0.030)

– Infusion site swelling

8 (16.3)

124 (0.118)

– Infusion site bruising

8 (16.3)

26 (0.025)

Parameters
Systemic AEs

All local infusion site reactions

– Infusion site nodule

8 (16.3)

13 (0.012)

– Infusion site pruritus

5 (10.2)

28 (0.027)

– Infusion site induration

4 (8.2)

6 (0.006)

– Infusion site scab

3 (6.1)

6 (0.006)

– Infusion site edema

3 (6.1)

5 (0.005)

† Including all systemic AEs and local infusion site reactions (regardless of whether they met the definition of AEs) that occurred after the first dose of IGSC-C 20% regardless of causality,
excluding infections.
‡ Number and percentage of participants with the event.
§ Rate per infusion is calculated as the total number of events divided by the total number of infusions.
AE: Adverse event; IGSC-C 20%: Immune globulin subcutaneous (human), 20% caprylate/chromatography purified (Grifols); IV: Intravenous; NA: Not applicable; SAE: Serious adverse
event; SC: Subcutaneous.

Excluding the SBIs discussed above, one participant reported a serious adverse event (SAE) during the SC phase.
This SAE was intervertebral disc degeneration, which was considered unrelated to the study drug by the investigator.
No SAE occurred in the run-in phase. There was no potentially related SAE, no death, no thromboembolic AEs
and no fatigue reported during any study phases.
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In the IV phase, one participant withdrew from the study due to two concurrent SBIs that were considered
moderate in severity and not related to study drug. Four participants withdrew from the study during the SC phase.
Of those, three participants had three nonserious local ISRs or infusion-related AEs that were considered mild or
moderate in severity and definitely related to study drug. One participant reported arthralgia and myalgia that was
considered nonserious, moderate in severity and possibly related to study drug. All but two (infusion site nodules)
of the AEs resolved. There were no noticeable differences in the AE profiles for the individual age groups (data not
shown).

Discussion
Overall this study had a rigorous design, as only patients with confirmed hypogammaglobulinemia were enrolled
to ensure the accuracy of the pharmacokinetic determinations. A key feature was the run-in phase with a 10%
IGIV preparation that had a similar formulation to the 20% IGSC product. The pharmacokinetic outcomes were
comparable with other studies of IGSC [15,23,24]. At a dose conversion factor of 1.37, IGSC-C 20% provided
comparable (noninferior and bioequivalent) overall serum exposure to total IgG (AUC) relative to the IV dose of
IGIV-C 10% over an equal time interval. Steady-state mean trough total IgG following IGSC-C 20% administration
at 1.37-times the IV dose averaged 33% higher than the trough concentrations observed for the IGIV-C 10%
dose. The results indicate the primary PK end point (steady state AUC0–7 days ) is consistent across the three analyses
(range = 1.04–1.06), demonstrating the robustness of the analysis results. The lower bound of the 90% CI for the
GLSM ratio (SC/IV) was above 0.80, demonstrating noninferiority of IGSC-C 20% to IGIV-C 10%. In addition,
the overall 90% CI falls within the range of 0.80–1.25, an accepted criterion for ‘bioequivalence’ between the
two treatments based on regulatory guidelines [25]. The levels of IgG subclasses were consistent with a physiologic
distribution pattern (mean values) [26]. Furthermore, mean trough levels among the IgG subclasses displayed similar
PK between IGIV-C 10% and IGSC-C 20%. These results were expected due to the difference in half-life among
the IgG subclasses [27]. Current FDA guidelines require IGSC and IGIV preparations to demonstrate similar IgG
AUC, resulting in dosing adjustments ranging from 120 to 153%. Comparison of IgG trough and AUC between
the IGIV and IGSC products tested in this study reveals essentially a linear relationship between formulation and
overall bioavailability that is similar to other IGSC products [23,24,28–30].
The rate of SBIs per person per year was low for both SC and IV formulations, although the enrollment numbers
were too small to accurately determine efficacy in preventing SBIs. Overall rates of infections of validated infections
per person per year were similar between IGSC-C 20% and IGIV-C 10%. Furthermore, these rates are similar to
reported rates of SBI and other infections among other 20% IGSC products [15,24,31–35,24].
IGSC-C 20% administration was not associated with any reports of serious systemic or local ISRs; the majority
of nonserious local ISRs observed were mild to moderate, with an incidence that decreased over time (repeated SC
infusions). Infusion-related systemic AEs (i.e., headache) were low, <0.001 per infusion. The number, site locations
and infusion volume per site used by the participants varied among the cohort as both children and adults were
included in the study. Overall, most participants used abdomen or thighs as site locations, with the average volume
per site near 20 ml, but with a high degree of individual variation. The average infusion rate at just over an hour
allows for convenient infusions in the home care setting.
It is important to keep in mind that participants received many more SC infusions (n = 1053) than IV infusions
(n = 261), and this difference in the number of infusions for the two treatment groups contributed to the lower
calculated rate of AEs per infusion for SC administration (0.134 event per infusion) relative to IV administration
(0.303 event per infusion). On the other hand, it could also have contributed to the higher rate of AEs during or
within 72 h of an infusion in the SC phase.
SC administration of IGSC-C 20% maintained equivalent exposure to IGIV-C 10% administered IV, with
higher mean trough values and lower fluctuations in IgG concentrations. Administration in the home care setting
was tolerated in both children and adults enrolled in the study. Before the approval of this study product in
R
20% [32], a
July 2019, there were two FDA-approved IGSC-C 20% products available in the USA: Hizentra
R

proline-stabilized IGSC (CSL Behring, approved 2010) and Cuvitru 20% [10], a glycine-stabilized IGSC (Baxalta,
approved 2016). Overall, the rates of infections and SBIs in participants given IGSC-C 20% as IgG replacement
therapy for immune prophylaxis were low and comparable with other subcutaneous IgG products.
This study was designed in accordance with FDA guidelines in terms of study design and end points and
included multiple centers. As such the limitations in the study were mainly with regard to the youngest age category
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(2–5 years), wherein two patients enrolled and one completed study. Thus, the results for very young children were
limited within the confines of this trial alone.
Another Phase III study (NCT02806986) that was designed according to European Medicines Agency guidelines,
employing a 1:1 DAF, recently completed clinical phase in Europe. We anticipate that results from this study will
further guide physicians on how to treat PI using IGSC-C 20%.
In conclusion, subcutaneous administration of IGSC-C 20% was safe and well tolerated with a safety profile
comparable to IV administration of IGIV-C 10%.
Summary points
• Immune globulin subcutaneous, human – klhw (IGSC-C 20%) is a 20% immunoglobulin G (IgG) solution for
subcutaneous injection that is US FDA-approved for the treatment of primary humoral immunodeficiency (PI) in
patients 2 years of age and older.
• This study was a prospective, multicenter, open-label and Phase III clinical trial (NCT02604810) evaluating the
pharmacokinetics, safety and tolerability of IGSC-C 20%, compared with immune globulin injection (human),
10% caprylate/chromatography purified (IGIV-C 10%), in patients with PI.
• Subcutaneous (SC) administration of IGSC-C 20% maintained equivalent exposure to IGIV-C 10% administered IV,
with higher mean trough values (SC:IV of 1.333) and lower fluctuations in IgG concentrations.
• The average (standard deviation) of the steady-state mean trough concentrations of total IgG over all participants
was approximately 957 (242) mg/dl for IGIV-C 10% and approximately 1245 (272) mg/dl for IGSC-C 20%.
• IGSC-C 20% was safe and well tolerated with a safety profile comparable to IV administration of IGIV-C 10%.
• SBIs per person per year were 0.120 (95% CI: 0.051–0.232; upper 99% confidence limit: 0.259) in the IGIV-C 10%
Run-in + IV phase and 0.049 (95% CI, 0.020–0.098; upper 99% confidence limit: 0.110) on IGSC-C 20% treatment.
• The rate of infections per person per year was comparable between IGIV-C 10% treatment (0.658 [95% CI,
0.378–1.051]) and IGSC-C 20% treatment (0.493 [95% CI, 0.273–0.809]).
• Serum trough concentrations of antibody for H. influenzae, C. tetani, and S. pneumoniae increased after
switching from IV to SC phases and were generally consistent across all age groups. The trough concentrations of
measles antibody were comparable between the IV and SC phases and were protective.
• A total of 79 adverse events (AEs) occurred in 62.3% (33 of 53, 0.303 event per infusion) of participants during
IGIV-C 10% treatment, and 141 AEs occurred in 83.7% (41 of 49, 0.134 event per infusion) of the participants
during IGSC-C 20% treatment—most of which were local infusion site AEs associated with the SC route of
administration.
• The majority of AEs (98.7% for IGIV-C 10%; 96.5% for SC) were mild or moderate in severity.
• There was no potentially related serious AEs or death reported in this study.
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